BUZZ-INmune Bio rises as prostate cancer therapy meets trial goals
Reuters
Aug 04
BUZZ-INmune Bio rises as prostate cancer therapy meets trial goals
** Shares of drug developer INmune Bio INMB.O rise 7% to $2.74 in early trade
** Co says its therapy for a type of prostate cancer has met the main and secondary goals of an early-to-mid-stage study
** INMB says the therapy, INKmune, "was well tolerated at all three dose levels in the trial, demonstrating an excellent safety profile," which was the main goal of the trial
** As a result, co stops further enrollment into the study
** Including session's moves, stock down 41.3% YTD
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.